Compr Ophthalmol Update. 2005;6(1):11-21. As can be seen in Table 2, untreated cases of TON improve even when the initial vision is no light perception. This rate of spontaneous visual improvement ...
In this Healio Video Perspective from Hawaiian Eye 2025, Riad Sherif, MD, CEO of Oculis, discusses data on OCS-05 for the ...
Beyond identifying corporate partners for the development and commercialization of ST266 for optic neuritis, glaucoma or age-related macular degeneration, Noveome is also exploring the use of ...
The trial met safety and efficacy endpoints. OCS-05 met safety and efficacy endpoints in the treatment of acute optic neuritis in a phase 2 trial, according to a press release from Oculis.
OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback